Team:NTU-Taida/Project/Effector

From 2012.igem.org

(Difference between revisions)
(Created page with "{{:Team:NTU-Taida/Templates/Header}}{{:Team:NTU-Taida/Templates/Navbar}}{{:Team:NTU-Taida/Templates/Sidebar|Title=Effector}}{{:Team:NTU-Taida/Templates/ContentStart}} {{:Team:NT...")
Line 5: Line 5:
==Glucagon-like Peptide-1 (GLP-1)==
==Glucagon-like Peptide-1 (GLP-1)==
-
 
+
'''Glucagon-like Peptide-1 (GLP-1)''' is one of the members of '''incretin''', a group of gastrointestinal hormones secreted by endocrine cells in small intestine that mainly work to increase insulin levels. Under normal physiological condition, this 30-amino acid peptide is secreted by L cells, a kind of neuroendocrine cell located in small intestine after a meal, into the circulation, promoting insulin release and inhibit energy intake. Its natural form can be degraded by DPP-4, having a half life of 1-2 minutes. GLP-1 mainly acts on the '''GLP-1 receptor''', a G-protein coupled receptors, coupled with adenylyl cyclase downstream and signaling on PI3K/Akt and ERK1/2 pathways via second messenger cAMP. It promotes the secretion of insulin in β cells of islets in pancreas, antagonizes and glucose-rising effect of glucagon, and largely increase the insulin sensitivity of targeted cells. GLP-1 analogues such as Liraglutide and Exentide  and DPP-4 inhibitors have been used clinically as treatment for patients with '''type 2 diabetes mellitus (T2DM)''', but recently, more and more focus has been spotted on its versatile functions, such as cardiovascular regulation, appetite inhibition, and neuroprotective effects. Here we aim to utilize the functions in appetite inhibition and neuroprotection of GLP-1, in order to tailor our PEPDEX as a living machine that communicate with our central nervous systems and modulate our eating behavior, as well as improve our cognitive function to prevent neurodegenerative diseases.
==Fat Extinguisher—Reduction in Eating Behavior==
==Fat Extinguisher—Reduction in Eating Behavior==
 +
Obesity and metabolic syndrome have been regarded as chronic disease recent decades. It is reported that people with obesity or metabolic syndromes are in a higher risk of type II diabetes, cardiovascular disease and hypertension. Nowadays, there are 1 billion people encountering over-weight problem, and 30 million people are diagnosed of obesity. Modern dietary pattern has been considered the major cause contributing to the phenomena.
 +
GLP-1 is known to act on the satiety center inside hypothalamic regions of brains, inhibiting appetite and modulating feeding behavior. Therapeutic use of anti-obesity has also been proved by different drug authorities. In PepdEx, we put GLP-1 production under the control of a circuit with a fatty acid sensor, mimicking the physiological response that GLP-1 is released after food intake. Induced by a fat meal, bacterial secreted GLP-1 are expected to penetrate the intestinal epithelium with the assistance of cell penetrating peptide Penetratin, circulating to the brain and perform its behavior-regulating function.
==Brain Guardian—Memory Improvement and Neuroprotection ==
==Brain Guardian—Memory Improvement and Neuroprotection ==
 +
Besides regulation of appetite, GLP-1 also has wide effects on the central nervous system, including promotion of learning and memory and neuroprotective roles. GLP-1 receptors are distributed among the brain in various regions such as hypothalamus, thalamus, brainstem, and hippocampus. Studies using in vitro culture and animal models indicate that GLP-1 promote the learning and memory function in CA1 region of hippocampus, via increase of long-term potentiation (LTP) and enhancement of synaptic plasticity. It also reduces the destructive effects of Aβ amyloid and preserve and dopaminergic neurons in Alzheimer’s disease and Parkinson’s disease, respectively. Potentiation of neuronal differentiation, promotion of cell survival, up-regulation of neurotransmitter synthesis and modulation of glial cells are other functions of GLP-1 in CNS that have been reported, while more diseases such as Huntington’s disease, stroke, and peripheral sensory neuropathy potentially become its therapeutic targets. Conjugation with a thermal regulatory promoter gives a constitutive delivery of GLP-1 inside the human body, which constantly stimulates and protects the CNS, in improvement of learning and memory and prevention of neurodegenerative diseases.
 +
<ol>
 +
  <li>1.  De Silva A, et al. (2011) The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans. Cell Metab 14(5):700-6.</li>
 +
</ol>
==Cell Penetrating Peptide (CPP)==
==Cell Penetrating Peptide (CPP)==

Revision as of 14:32, 26 October 2012

Effector

Effector


Contents

Glucagon-like Peptide-1 (GLP-1)

Glucagon-like Peptide-1 (GLP-1) is one of the members of incretin, a group of gastrointestinal hormones secreted by endocrine cells in small intestine that mainly work to increase insulin levels. Under normal physiological condition, this 30-amino acid peptide is secreted by L cells, a kind of neuroendocrine cell located in small intestine after a meal, into the circulation, promoting insulin release and inhibit energy intake. Its natural form can be degraded by DPP-4, having a half life of 1-2 minutes. GLP-1 mainly acts on the GLP-1 receptor, a G-protein coupled receptors, coupled with adenylyl cyclase downstream and signaling on PI3K/Akt and ERK1/2 pathways via second messenger cAMP. It promotes the secretion of insulin in β cells of islets in pancreas, antagonizes and glucose-rising effect of glucagon, and largely increase the insulin sensitivity of targeted cells. GLP-1 analogues such as Liraglutide and Exentide and DPP-4 inhibitors have been used clinically as treatment for patients with type 2 diabetes mellitus (T2DM), but recently, more and more focus has been spotted on its versatile functions, such as cardiovascular regulation, appetite inhibition, and neuroprotective effects. Here we aim to utilize the functions in appetite inhibition and neuroprotection of GLP-1, in order to tailor our PEPDEX as a living machine that communicate with our central nervous systems and modulate our eating behavior, as well as improve our cognitive function to prevent neurodegenerative diseases.

Fat Extinguisher—Reduction in Eating Behavior

Obesity and metabolic syndrome have been regarded as chronic disease recent decades. It is reported that people with obesity or metabolic syndromes are in a higher risk of type II diabetes, cardiovascular disease and hypertension. Nowadays, there are 1 billion people encountering over-weight problem, and 30 million people are diagnosed of obesity. Modern dietary pattern has been considered the major cause contributing to the phenomena. GLP-1 is known to act on the satiety center inside hypothalamic regions of brains, inhibiting appetite and modulating feeding behavior. Therapeutic use of anti-obesity has also been proved by different drug authorities. In PepdEx, we put GLP-1 production under the control of a circuit with a fatty acid sensor, mimicking the physiological response that GLP-1 is released after food intake. Induced by a fat meal, bacterial secreted GLP-1 are expected to penetrate the intestinal epithelium with the assistance of cell penetrating peptide Penetratin, circulating to the brain and perform its behavior-regulating function.

Brain Guardian—Memory Improvement and Neuroprotection

Besides regulation of appetite, GLP-1 also has wide effects on the central nervous system, including promotion of learning and memory and neuroprotective roles. GLP-1 receptors are distributed among the brain in various regions such as hypothalamus, thalamus, brainstem, and hippocampus. Studies using in vitro culture and animal models indicate that GLP-1 promote the learning and memory function in CA1 region of hippocampus, via increase of long-term potentiation (LTP) and enhancement of synaptic plasticity. It also reduces the destructive effects of Aβ amyloid and preserve and dopaminergic neurons in Alzheimer’s disease and Parkinson’s disease, respectively. Potentiation of neuronal differentiation, promotion of cell survival, up-regulation of neurotransmitter synthesis and modulation of glial cells are other functions of GLP-1 in CNS that have been reported, while more diseases such as Huntington’s disease, stroke, and peripheral sensory neuropathy potentially become its therapeutic targets. Conjugation with a thermal regulatory promoter gives a constitutive delivery of GLP-1 inside the human body, which constantly stimulates and protects the CNS, in improvement of learning and memory and prevention of neurodegenerative diseases.

  1. 1. De Silva A, et al. (2011) The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans. Cell Metab 14(5):700-6.

Cell Penetrating Peptide (CPP)

Secretion

Type 2 Secretion System (T2SS)

Signal Peptides

Signal Peptide Source Sequence
SP1 PhoA MKQSTIALALLPLLFTPVTKA
SP2 LTB MNKVKCYVLFTALLSSLYAHG
SP3 StII MKKNIAFLLASMFVFSIATNAYA

Reference